The Analyst Landscape: 15 Takes On Johnson & Johnson

Dec 10, 2024 · Ratings for Johnson & Johnson (NYSE:JNJ) were provided by 15 analysts in the past three months, ... The Analyst Landscape: 15 Takes On Johnson & Johnson December …

CouponFollow Extension

$202.33
OFF

A Closer Look At 9 Analyst Recommendations For Johnson

2 weeks from now

Apr 15, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $202.33, a high estimate of $215.00, and a low estimate of $169.00.

businessinsider.com

2%
OFF

Johnson & Johnson Prioritizes Sustainable Growth In M&A Amid …

2 weeks from now

Jul 18, 2024 · Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A …

businessinsider.com

1%
OFF

Why Traders Are Buying The Dip On Johnson & Johnson Stock

2 weeks from now

Jan 25, 2025 · Those from Swedbank decided to boost their Johnson & Johnson stock holdings by as much as 2.1% as of January 2025, bringing their net position to a high of $326.9 million …

benzinga.com

$245.00
OFF

The Analyst Landscape: 45 Takes On Tesla - Nasdaq

2 weeks from now

Oct 11, 2024 · Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target; Andres Sheppard: Cantor Fitzgerald: Maintains: Neutral: $245.00: $245.00: William Stein: …

nasdaq.com

FAQs about The Analyst Landscape: 15 Takes On Johnson & Johnson Coupon?

Why do analysts'maintain' or 'raise' their stance on Johnson & Johnson?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson & Johnson. ...

What does a Johnson & Johnson analyst comparison reveal?

This comparison reveals trends in analysts' expectations over time. Capture valuable insights into Johnson & Johnson's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table. Stay up to date on Johnson & Johnson analyst ratings. ...

Does Johnson & Johnson's M&A strategy continue after acquiring Shockwave medical?

They expect the third quarter to follow typical seasonal patterns without backlog issues, with robust MedTech markets projected for 2024 and beyond. Johnson & Johnson maintains its consistent M&A strategy, affirming continuity even after acquiring Shockwave Medical. ...

Does Johnson & Johnson (JNJ) expect a favorable second-quarter environment?

Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70. RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China. ...

What is a Johnson & Johnson SWOT analysis?

This Johnson & Johnson SWOT analysis will explore the corporation’s internal strengths and weaknesses and the external opportunities and threats that could shape its future endeavors. Renowned as a global leader in the healthcare sector, Johnson & Johnson (J&J) has built a legacy that spans more than 135 years. ...

Is Johnson & Johnson a good stock to buy in 2024?

Johnson & Johnson anticipates faster sales growth in its Medical Technology sector in the second half of 2024. However, it foresees a slowdown in sales growth for Innovative Medicine, mainly due to the entry of a biosimilar for Stelara in Europe. RBC Capital maintains the Outperform rating with a price target of $175. ...